EUVIMEDEUVIMED entdecken
Crossref

Evaluation of a monoclonal antibody against respiratory syncytial virus, clesrovimab, in infants and children: Comprehensive rationale and study design for the late-stage clinical trials

Anushua Sinha, Radha A Railkar, Luis Castagnini, Andrea Guerra, Andrea Likos, Jeannine Lutkiewicz, Brian M Maas, Xiaowei Zang, Brad A Roadcap, Yoonyoung Choi, Georges J Nahhas, Carmen S Arriola und 6 weitere

Contemporary Clinical Trials · 2025

DOI: 10.1016/j.cct.2025.107995 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Contemporary Clinical Trials, 2025. Verfasst von Anushua Sinha und 17 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co., Inc., Rahway, NJ, USA. Electronic address: anushua.sinha@merck.com. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Antibodies, Monoclonal, Humanized, Antiviral Agents, Antibodies, Monoclonal. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Merck Sharp and Dohme United Kingdom.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Respiratory syncytial virus (RSV) is a leading cause of infant morbidity and mortality. Clesrovimab is a half-life-extended, RSV neutralizing monoclonal antibody for the prevention of RSV disease in infants. This article describes the methodology that enabled the acceleration of two pivotal late-stage clinical trials, CLEVER (MK-1654-004; NCT04767373) and SMART (MK-1654-007; NCT04938830), for the evaluation of clesrovimab. METHODS: CLEVER is a placebo-controlled phase 2b/3 study in healthy preterm and full-term infants, evaluating the efficacy and safety of clesrovimab for the prevention of RSV-associated medically attended lower respiratory tract infection (RSV-MALRI) and RSV-associated hospitalization. SMART is a phase 3 palivizumab-controlled study evaluating the safety, tolerability, and efficacy of clesrovimab, compared with palivizumab, for the prevention of RSV-associated MALRI and RSV-associated hospitalization in infants and children at increased risk of severe RSV disease. Dose selection in these studies was informed using a model-based meta-analysis of phase 1 and 2 clesrovimab trial data. Program acceleration was enabled by designing CLEVER seamlessly, to rapidly progress from phase 2b to phase 3. Additionally, efficacy was extrapolated to the SMART population, based on pharmacokinetic bridging between CLEVER and SMART. CONCLUSION: The methodology of the accelerated late-stage development of clesrovimab, including the model-informed dose selection approach, the seamless enrollment in the phase 3 portion of CLEVER, and the extrapolation of efficacy from the population in CLEVER to the population in SMART, may be used to inform future trial designs where acceleration is needed to address an unmet medical need.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsAntibodies, Monoclonal, HumanizedAntiviral AgentsAntibodies, MonoclonalHumansInfantPalivizumabDouble-Blind MethodClinical Trials, Phase II as TopicInfant, NewbornChildResearch DesignClinical Trials, Phase III as TopicChild, PreschoolInfant, PrematureRandomized Controlled Trials as TopicMaleRespiratory Syncytial Virus, HumanHospitalizationFemale

Stichwörter der Autor:innen

Drug developmentModelingMonoclonal antibodyPediatricsRespiratory infectionsRespiratory syncytial virus

Substanzen

PalivizumabAntibodies, Monoclonal, HumanizedAntiviral AgentsAntibodies, Monoclonal

Autor:innen und Institutionen

  • Merck & Co., Inc., Rahway, NJ, USA. Electronic address: anushua.sinha@merck.com.
  • Merck & Co., Inc., Rahway, NJ, USA.
  • Department of Pediatrics, University Medical Center, Utrecht, the Netherlands; ReSViNET Foundation, Zeist, the Netherlands.
  • ReSViNET Foundation, Zeist, the Netherlands; Department of Maternal-Infant Medicine, University Hospital 'Degli Infermi', Ponderano (Biella), Italy; University of Torino School of Medicine, Torino, Italy.
  • Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA.

Förderung

  • Merck Sharp and Dohme United Kingdom

Zitieren

APA

Sinha, A., Railkar, R. A., Castagnini, L., Guerra, A., Likos, A., Lutkiewicz, J., Maas, B. M., Zang, X., Roadcap, B. A., Choi, Y., Nahhas, G. J., Arriola, C. S., Bont, L., Manzoni, P., Ramilo, O., Muñoz, F. M., Finelli, L., & Lee, A. W. (2025). Evaluation of a monoclonal antibody against respiratory syncytial virus, clesrovimab, in infants and children: Comprehensive rationale and study design for the late-stage clinical trials. Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2025.107995

Vancouver

Sinha A, Railkar RA, Castagnini L, Guerra A, Likos A, Lutkiewicz J, et al. Evaluation of a monoclonal antibody against respiratory syncytial virus, clesrovimab, in infants and children: Comprehensive rationale and study design for the late-stage clinical trials. Contemporary Clinical Trials. 2025. doi:10.1016/j.cct.2025.107995

BibTeX
@article{Sinha2025,
  author = {Sinha, Anushua and Railkar, Radha A and Castagnini, Luis and Guerra, Andrea and Likos, Andrea and Lutkiewicz, Jeannine and Maas, Brian M and Zang, Xiaowei and Roadcap, Brad A and Choi, Yoonyoung and Nahhas, Georges J and Arriola, Carmen S and Bont, Louis and Manzoni, Paolo and Ramilo, Octavio and Muñoz, Flor M and Finelli, Lyn and Lee, Andrew W},
  title = {Evaluation of a monoclonal antibody against respiratory syncytial virus, clesrovimab, in infants and children: Comprehensive rationale and study design for the late-stage clinical trials},
  journal = {Contemporary Clinical Trials},
  year = {2025},
  doi = {10.1016/j.cct.2025.107995}
}
Kostenlos starten →